Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW, Sia KCS, Jones C, Evans K, Mariana A, Pang I, Failes T, Zhong L, Mayoh C, Landman R, Collins R, Erickson SW, Arndt G, Raftery MJ, Wilkins MR, Norris MD, Haber M, Marshall GM, Lock RB. Bӧhm JW, et al. Among authors: erickson sw. Leukemia. 2021 Nov;35(11):3101-3112. doi: 10.1038/s41375-021-01248-8. Epub 2021 Apr 24. Leukemia. 2021. PMID: 33895784
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
Evans K, Duan J, Pritchard T, Jones CD, McDermott L, Gu Z, Toscan CE, El-Zein N, Mayoh C, Erickson SW, Guo Y, Meng F, Jung D, Rathi KS, Roberts KG, Mullighan CG, Shia CS, Pearce T, Teicher BA, Smith MA, Lock RB. Evans K, et al. Among authors: erickson sw. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503. doi: 10.1158/1078-0432.CCR-19-0551. Epub 2019 Apr 23. Clin Cancer Res. 2019. PMID: 31015346 Free PMC article.
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.
Somers K, Evans K, Cheung L, Karsa M, Pritchard T, Kosciolek A, Bongers A, El-Ayoubi A, Forgham H, Middlemiss S, Mayoh C, Jones L, Gupta M, Kees UR, Chernova O, Korotchkina L, Gudkov AV, Erickson SW, Teicher B, Smith MA, Norris MD, Haber M, Lock RB, Henderson MJ. Somers K, et al. Among authors: erickson sw. Leukemia. 2020 Jun;34(6):1524-1539. doi: 10.1038/s41375-019-0683-6. Epub 2019 Dec 17. Leukemia. 2020. PMID: 31848452 Free PMC article.
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Kurmasheva RT, Bandyopadhyay A, Favours E, Del Pozo V, Ghilu S, Phelps DA, Erickson SW, Peer CJ, Figg WD, Smith MA, Houghton PJ. Kurmasheva RT, et al. Among authors: erickson sw. Pediatr Blood Cancer. 2019 Aug;66(8):e27820. doi: 10.1002/pbc.27820. Epub 2019 May 16. Pediatr Blood Cancer. 2019. PMID: 31099166 Free PMC article.
Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium.
Nevil G, Roth M, Gill J, Zhang W, Teicher B, Erickson SW, Gatto G, Smith M, Kolb EA, Gorlick R. Nevil G, et al. Among authors: erickson sw. Pediatr Hematol Oncol. 2021 Feb;38(1):8-13. doi: 10.1080/08880018.2020.1802539. Epub 2020 Aug 17. Pediatr Hematol Oncol. 2021. PMID: 32804009 Free PMC article.
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.
Kurmasheva RT, Erickson SW, Earley E, Smith MA, Houghton PJ. Kurmasheva RT, et al. Among authors: erickson sw. Pediatr Blood Cancer. 2021 Feb;68(2):e28772. doi: 10.1002/pbc.28772. Epub 2020 Oct 22. Pediatr Blood Cancer. 2021. PMID: 33089597 Free PMC article.
83 results